ZOLLY is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.
ZOLLY modulates the alpha-subunit, known as the benzodiazepine receptor, within the GABAA receptor chloride channel macromolecular complex. Unlike the benzodiazepines, which non-selectively interact with all three alpha-receptor subtypes, ZOLLY preferentially binds to the alpha-1 receptor.
ZOLLY is rapidly absorbed from the GI tract Protein binding: 92.5 ± 0.1% ZOLLY is converted to inactive metabolites in the liver. Route of elimination: ZOLLY tablets are converted to inactive metabolites that are eliminated primarily by renal excretion. Half-life: 2.6 hours
The recommended initial dose is 5mg for women and either 5 or 10mg for men, taken only once per night immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening. If the 5mg dose is not effective, the dose can be increased to 10mg. in some patients, the higher morning blood levels following use of the 10mg dose increase the risk of next day impairment of driving and other activities that require alertness. The total dose of ZOLLY should not exceed 10mg once daily. The recommended initial doses for women and men are different because ZOLLY clearance is lower in women. Elderly or debilitated patients may be especially sensitive to the effects of ZOLLY. Patients with hepatic insufficiency do not clear the drug as rapidly as normal subjects. The recommended dose of ZOLLY in both of these patient populations is 5mg once daily immediately before bedtime. Dosage adjustment may be necessary when ZOLLY is combined with other CNS depressant drugs because of the potentially additive effects.
The available dose is 10mg tablet. Each strip contains 10 tablets